The chart of Cronos Group Inc. (CRON) shows a double top with $11.13 target or 9.00 % above today’s $10.21 share price.

The 8 months chart pattern indicates low risk for the $1.82 billion company. It was reported on Dec, 23 by Finviz.com. If the $11.13 price target is reached, the company will be worth $163.53M more.

Double tops are rare but powerful chart patterns.

The stock decreased 8.27% or $0.92 during the last trading session, reaching $10.21. About 6.91 million shares traded. Cronos Group Inc. (NASDAQ:CRON) has risen 277.71% since December 23, 2017 and is uptrending. It has outperformed by 277.71% the S&P500.

Analysts await Cronos Group Inc. (NASDAQ:CRON) to report earnings on April, 29. They expect $-0.01 EPS, down 200.00 % or $0.02 from last year’s $0.01 per share. After $-0.03 actual EPS reported by Cronos Group Inc. for the previous quarter, Wall Street now forecasts -66.67 % EPS growth.

More notable recent Cronos Group Inc. (NASDAQ:CRON) news were published by: Schaeffersresearch.com which released: “2 Pot Stocks Making Massive Moves Today – Schaeffers Research” on December 03, 2018, also Investorplace.com with their article: “Will Aurora Cannabis Be Next to Secure a Big Partnership? – Investorplace.com” published on December 21, 2018, Investorplace.com published: “Check Your Risk Tolerance Before Inhaling Aphria Stock – Investorplace.com” on December 18, 2018. More interesting news about Cronos Group Inc. (NASDAQ:CRON) were released by: Fool.com and their article: “The 12 Largest Marijuana Stocks – The Motley Fool” published on December 01, 2018 as well as Investorplace.com‘s news article titled: “3 Reasons Why You Shouldn’t Panic About Cronos Stock – Investorplace.com” with publication date: December 13, 2018.

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The company has market cap of $1.82 billion. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations . It currently has negative earnings. The firm typically invests in companies based in Canada.